KR100558506B1 - 과도한 물질 ｐ에 의해 야기된 문제점을 치료하기 위한약물 제조에 사용되는 아릴(또는헤테로아릴)아졸일카르비놀 유도체의 용도 - Google Patents

과도한 물질 ｐ에 의해 야기된 문제점을 치료하기 위한약물 제조에 사용되는 아릴(또는헤테로아릴)아졸일카르비놀 유도체의 용도 Download PDF

Info

Publication number
KR100558506B1
KR100558506B1 KR1020017001560A KR20017001560A KR100558506B1 KR 100558506 B1 KR100558506 B1 KR 100558506B1 KR 1020017001560 A KR1020017001560 A KR 1020017001560A KR 20017001560 A KR20017001560 A KR 20017001560A KR 100558506 B1 KR100558506 B1 KR 100558506B1
Authority
KR
South Korea
Prior art keywords
methyl
imidazole
dimethylamino
benzyl
pyrazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020017001560A
Other languages
English (en)
Korean (ko)
Other versions
KR20010079616A (ko
Inventor
라몬 메르세-비달
조르디 프리골라-콘스탄사
Original Assignee
라보라토리오스 델 드라. 에스테브.에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 라보라토리오스 델 드라. 에스테브.에스.에이. filed Critical 라보라토리오스 델 드라. 에스테브.에스.에이.
Publication of KR20010079616A publication Critical patent/KR20010079616A/ko
Application granted granted Critical
Publication of KR100558506B1 publication Critical patent/KR100558506B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020017001560A 1998-08-07 1999-08-05 과도한 물질 ｐ에 의해 야기된 문제점을 치료하기 위한약물 제조에 사용되는 아릴(또는헤테로아릴)아졸일카르비놀 유도체의 용도 Expired - Fee Related KR100558506B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES009801708A ES2150378B1 (es) 1998-08-07 1998-08-07 Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p.
ESP9801708 1998-08-07

Publications (2)

Publication Number Publication Date
KR20010079616A KR20010079616A (ko) 2001-08-22
KR100558506B1 true KR100558506B1 (ko) 2006-03-07

Family

ID=8304839

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017001560A Expired - Fee Related KR100558506B1 (ko) 1998-08-07 1999-08-05 과도한 물질 ｐ에 의해 야기된 문제점을 치료하기 위한약물 제조에 사용되는 아릴(또는헤테로아릴)아졸일카르비놀 유도체의 용도

Country Status (26)

Country Link
US (1) US6518295B1 (https=)
EP (1) EP1103243B1 (https=)
JP (1) JP2002522359A (https=)
KR (1) KR100558506B1 (https=)
CN (1) CN1151789C (https=)
AR (1) AR019999A1 (https=)
AT (1) ATE257379T1 (https=)
AU (1) AU754124B2 (https=)
BR (1) BR9912807A (https=)
CA (1) CA2339661C (https=)
CO (1) CO5080747A1 (https=)
CZ (1) CZ292065B6 (https=)
DE (1) DE69914085T8 (https=)
DK (1) DK1103243T3 (https=)
ES (2) ES2150378B1 (https=)
HU (1) HUP0105428A3 (https=)
IL (1) IL141295A0 (https=)
NO (1) NO20010634L (https=)
NZ (1) NZ509645A (https=)
PL (1) PL193802B1 (https=)
PT (1) PT1103243E (https=)
RU (1) RU2223116C2 (https=)
TR (1) TR200100378T2 (https=)
TW (1) TW445259B (https=)
WO (1) WO2000007542A2 (https=)
ZA (1) ZA200100867B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2174756B2 (es) * 2001-04-06 2003-11-16 Esteve Labor Dr Derivados de aril (o heteroaril) azolilcarbinoles para el tratamiento de enfermedades respiratorias.
US20040142929A1 (en) * 2001-07-06 2004-07-22 Ramon Merce-Vidal Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence
ES2180449B1 (es) * 2001-07-06 2004-01-16 Esteve Labor Dr Derivados de aril (o heteroaril) azolilcarbinoles para el tratamiento de la incontinencia urinaria.
DE10335566A1 (de) * 2003-07-31 2005-02-24 Grünenthal GmbH Arzneimittel enthaltend Derivate von Aryl( oder Heteroaryl)azolylcarbinolen
EP1584335A3 (en) * 2004-04-05 2006-02-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising a carbinol composition and an opioid
ES2244326B1 (es) * 2004-04-05 2007-02-16 Laboratorios Del Dr. Esteve, S.A. Combinacion de substancias activas.
EP1784178A1 (en) * 2004-07-30 2007-05-16 Laboratorios Del Dr. Esteve, S.A. Aryl (or heteroaryl) azolylcarbinols
CA2580694A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
EP1690537A1 (en) * 2005-02-15 2006-08-16 Laboratorios Del Dr. Esteve, S.A. Derivatives of aryl(or heteroaryl) azolycarbinols for the treatment of fibromyalgia
ES2286920B1 (es) * 2005-02-15 2008-08-16 Laboratorios Del Dr. Esteve, S.A. Derivados de aril (o heteroaril)azolilcarbinoles para el tratamiento de la fibromialgia.
EP1695704A1 (en) * 2005-02-28 2006-08-30 Laboratorios Del Dr. Esteve, S.A. Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of fibromyalgia
WO2006087147A2 (en) * 2005-02-15 2006-08-24 Laboratorios Del Dr. Esteve, S.A. Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of fibromyalgia
AU2007209381A1 (en) * 2006-01-27 2007-08-02 F. Hoffmann-La Roche Ag Use of substituted 2-imidazole of imidazoline derivatives
EP1820502A1 (en) * 2006-02-10 2007-08-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising azolylcarbinol compounds
AU2007312390B2 (en) 2006-10-19 2013-03-28 F. Hoffmann-La Roche Ag Aminomethyl-4-imidazoles
CA2668454A1 (en) 2006-11-02 2008-05-08 F. Hoffmann-La Roche Ag Substituted 2-imidazoles
WO2008058867A2 (en) 2006-11-16 2008-05-22 F. Hoffmann-La Roche Ag Substituted 4-imidazoles
CN101190330A (zh) 2006-11-30 2008-06-04 深圳市鼎兴生物医药技术开发有限公司 胆碱酯酶在拮抗速激肽药物中的应用
ES2364701T3 (es) 2006-12-13 2011-09-12 F. Hoffmann-La Roche Ag Nuevos 2-imidazoles como ligandos para receptores asociados a aminas trazas.
EP2114906B1 (en) 2007-02-02 2014-08-06 F. Hoffmann-La Roche AG 2-aminooxazolines as taar1 ligands for cns disorders
CA2676944C (en) 2007-02-15 2016-01-19 F. Hoffmann-La Roche Ag 2-aminooxazolines as taar1 ligands
WO2009003868A2 (en) 2007-07-02 2009-01-08 F. Hoffmann-La Roche Ag 2 -imidazolines having a good affinity to the trace amine associated receptors (taars)
AU2008270444A1 (en) 2007-07-03 2009-01-08 F. Hoffmann-La Roche Ag 4-imidazolines and their use as antidepressants
CA2694362A1 (en) 2007-07-27 2009-02-05 F. Hoffmann-La Roche Ag 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as taar-ligands
AU2008285795A1 (en) 2007-08-03 2009-02-12 F. Hoffmann-La Roche Ag Pyridinecarboxamide and benzamide derivatives as TAAR1 ligands
US8242153B2 (en) 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
WO2010123999A2 (en) * 2009-04-21 2010-10-28 Auspex Pharmaceuticals, Inc. 1-methylpyrazole modulators of substance p, calcitonin gene-related peptide, adrenergic receptor, and/or 5-ht receptor
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
WO2017157873A1 (en) 2016-03-17 2017-09-21 F. Hoffmann-La Roche Ag 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2613720B1 (fr) * 1987-04-10 1990-01-19 Esteve Labor Dr Derives d'aryl-heteroaryl carbinols avec activite analgesique
FR2681322B1 (fr) * 1991-09-12 1993-12-17 Laboratorios Dr Esteve Sa Derives d'aryl-heteroaryl-{n-[2-(3,4-dimethoxyphenyl)-ethyl]-n-methyl-3-aminopropoxy}-methane leur preparation et leur application en tant que medicaments .
CA2154116A1 (en) * 1994-07-22 1996-01-23 Philip Arthur Hipskind 1-aryl-2-acetamidopentanone derivatives for use as tachykinin receptor antagonists
FR2742147B1 (fr) * 1995-12-06 1998-02-27 Esteve Labor Dr Procede de separation de carbinols
CA2273807A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating schizophrenic disorders
CA2273853A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating cognitive disorders
EP0942734A1 (en) * 1996-12-02 1999-09-22 MERCK SHARP & DOHME LTD. Use of nk-1 receptor antagonists for treating severe anxiety disorders
DE69732133T2 (de) * 1996-12-02 2005-12-22 Merck Sharp & Dohme Ltd., Hoddesdon Verwendung von NK-1 Rezeptorantagonisten zur Behandlung von schweren Depressionen
ES2150353B1 (es) * 1998-04-15 2001-07-01 Esteve Labor Dr Tienilazolilalcoxietanaminas, su preparacion y su aplicacion como medicamentos.

Also Published As

Publication number Publication date
ES2150378B1 (es) 2001-07-01
CO5080747A1 (es) 2001-09-25
EP1103243B1 (en) 2004-01-07
CZ2001412A3 (cs) 2001-08-15
KR20010079616A (ko) 2001-08-22
CA2339661A1 (en) 2000-02-17
ATE257379T1 (de) 2004-01-15
CN1151789C (zh) 2004-06-02
JP2002522359A (ja) 2002-07-23
ES2150378A1 (es) 2000-11-16
HUP0105428A3 (en) 2003-01-28
DK1103243T3 (da) 2004-05-03
BR9912807A (pt) 2001-10-16
AU5422999A (en) 2000-02-28
WO2000007542A2 (es) 2000-02-17
NO20010634L (no) 2001-04-06
AU754124B2 (en) 2002-11-07
PL346221A1 (en) 2002-01-28
US6518295B1 (en) 2003-02-11
WO2000007542A3 (es) 2000-05-11
TW445259B (en) 2001-07-11
NO20010634D0 (no) 2001-02-06
ZA200100867B (en) 2001-08-16
PL193802B1 (pl) 2007-03-30
CN1317966A (zh) 2001-10-17
DE69914085T8 (de) 2005-04-21
AR019999A1 (es) 2002-03-27
CA2339661C (en) 2006-10-17
IL141295A0 (en) 2002-12-01
RU2223116C2 (ru) 2004-02-10
CZ292065B6 (cs) 2003-07-16
EP1103243A2 (en) 2001-05-30
DE69914085D1 (de) 2004-02-12
NZ509645A (en) 2003-01-31
ES2213380T3 (es) 2004-08-16
TR200100378T2 (tr) 2001-06-21
DE69914085T2 (de) 2004-11-25
HUP0105428A2 (hu) 2002-05-29
PT1103243E (pt) 2004-05-31

Similar Documents

Publication Publication Date Title
KR100558506B1 (ko) 과도한 물질 ｐ에 의해 야기된 문제점을 치료하기 위한약물 제조에 사용되는 아릴(또는헤테로아릴)아졸일카르비놀 유도체의 용도
CN104334544B (zh) 苯并咪唑脯氨酸衍生物
JP2003509371A (ja) ５−ヒドロキシトリプタミン・レセプタ／α２アドレナリン作用性レセプタ拮抗薬組成物の投与による運動障害の処置
JP2002522359A5 (https=)
RU2001106644A (ru) Применение производных арил (или гетероарил) азолилкарбинолов в приготовлении лекарственного средства для лечения нарушений, опосредованных избытком вещества p
AU2007265088B2 (en) Method of modulating neurite outgrowth by the use of a galanin-3 receptor antagonist
EP1723117A2 (en) Ion channel modulators
US20050107356A1 (en) Combination of a CB1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease
EP1040829A2 (en) Prokinetic agents for treating gastric hypomotility and related disorders
WO1997021439A1 (fr) Medicament destine au traitement des troubles obsessifs compulsifs, de l'apnee du sommeil, des dysfonctions sexuelles, de l'emese et du mal des transports
KR102023748B1 (ko) 순수한 5-ht6 수용체 길항제 및 nmda 수용체 길항제의 조합물
CA2332711A1 (en) Use of derivatives of aryl(or heteroaryl)azolylcarbinols in the manufacture of a medicament for the treatment of neurogenic inflammation
CZ355998A3 (cs) Pyridil a pyrimidylpiperaziny pro léčení poruch způsobených odejmutím drogy
AU2005222399A1 (en) Ion channel modulators
CN101600474A (zh) 用于治疗心血管疾病的1,3-二氢咪唑类
MXPA01001438A (en) Utilization of aryl(or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of troubles mediated by an excess of substance p
ES2286920B1 (es) Derivados de aril (o heteroaril)azolilcarbinoles para el tratamiento de la fibromialgia.
CN101466685A (zh) 酶抑制剂
AU2018229062A1 (en) Therapeutic agent for alcohol use disorders

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20090301

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20090301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000